FIRST: Intas Pharma launches Oral Azacitidine under brand name Azadine-O
Ahmedabad: In a significant development, drugmaker Intas Pharma has announced the launch of Oral Azacitidine in India under the brand name of Azadine-O.With this INTAS becomes India's first pharmaceutical company to launch Oral Azacitidine. This progressive breakthrough will improve the survival period and quality of life of Acute Myeloid Leukemia patients."The company takes a revolutionary...
Ahmedabad: In a significant development, drugmaker Intas Pharma has announced the launch of Oral Azacitidine in India under the brand name of Azadine-O.
With this INTAS becomes India's first pharmaceutical company to launch Oral Azacitidine. This progressive breakthrough will improve the survival period and quality of life of Acute Myeloid Leukemia patients.
"The company takes a revolutionary step towards making therapy for Acute Myeloid Leukemia (a type of blood cancer) more accessible to patients by being the first to launch Oral Azacitidine in India under the brand name of Azadine-O," the company said in its recent release.
Oral Azacitidine is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. It is the first drug that will improve survival by almost ten months and bridge a long-pending unmet need in cancer therapy.
In 2014, Intas triggered a paradigm change in the treatment of MDS - myelodysplastic syndrome with the launch of AZADINE (Injectable Azacitidine). Azadine-O is yet another progressive breakthrough in the treatment of Acute Myeloid Leukemia.
Prof. (Dr) M. B. Agarwal, India's leading Haematologist, shared his views about the launch, saying, "Oral Azacitidine will prove to be extremely useful for AML patients. There was a dire need for this drug. It shall significantly improve survival and quality of life of patients."
Medical Dialogues team had earlier reported that Intas had got a green signal from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a study of rheumatoid arthritis drug Adalimumab.
Read also: Intas secures CDSCO panel nod to study arthritis drug Adalimumab
Read also: Intas Pharma, Meiji, Dong-A ST ink licensing agreement for biosimilar to Ustekinumab
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd